A carregar...

Carfilzomib/pomalidomide single-agent or in combination with other agents for the management of relapsed/refractory multiple myeloma: a meta-analysis of 37 trials

PURPOSE: The use of carfilzomib/pomalidomide single-agent or in combination with other agents in patients with refractory/relapsed multiple myeloma (RRMM) was not clearly clarified in clinical practice. We sought to compile the available clinical reports to better understand the efficacy and safety...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Oncotarget
Main Authors: Zou, Yandun, Ma, Xiaoyan, Yu, Haiying, Hu, Chunling, Fan, Limei, Ran, Xuehong
Formato: Artigo
Idioma:Inglês
Publicado em: Impact Journals LLC 2016
Assuntos:
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5503655/
https://ncbi.nlm.nih.gov/pubmed/27458170
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.10768
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!